Retinitis Pigmentosa – Epidemiology – Epidemiology – Retinitis Pigmentosa – Mature Markets
Clarivate Epidemiology’s coverage of retinitis pigmentosa comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of retinitis pigmentosa for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan in this report.
Clarivate Epidemiology’s retinitis pigmentosa forecast will answer the following questions:
- Of all people diagnosed with retinitis pigmentosa, how many in each country in the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of retinitis pigmentosa over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate’s Epidemiology provides at least ten years of forecast data for the following retinitis pigmentosa patient populations:
- Diagnosed inherited retinal dystrophy prevalent cases
- Diagnosed retinitis pigmentosa prevalent cases
- Diagnosed drug-treated cases of retinitis pigmentosa
- Clinical subtypes of retinitis pigmentosa
- Diagnosed Usher syndrome prevalent cases
- Diagnosed Bardet-Biedl syndrome prevalent cases
- Diagnosed prevalent cases with RPE65 mutation
- Diagnosed prevalent cases with RHO mutation
- Diagnosed Leber’s congenital amaurosis prevalent cases
- Diagnosed choroideremia prevalent cases
Note: Coverage may vary by country.
Table of contents
- Retinitis Pigmentosa - Epidemiology - Epidemiology - Retinitis Pigmentosa - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of retinitis pigmentosa)
- Diagnosed prevalent cases of inherited retinal dystrophy
- Diagnosed prevalent cases of retinitis pigmentosa
- Diagnosed prevalent cases of retinitis pigmentosa by clinical subtype
- Diagnosed prevalent cases of nonsyndromic retinitis pigmentosa by inheritance patterns
- Drug-treatable prevalent cases of X-linked nonsyndromic retinitis pigmentosa
- Diagnosed prevalent cases of RPE65-associated nonsyndromic autosomal recessive retinitis pigmentosa
- Drug-treatable prevalent cases of RPE65-associated nonsyndromic autosomal recessive retinitis pigmentosa
- Diagnosed prevalent cases of RHO-associated nonsyndromic autosomal-dominant RP
- Drug-treatable prevalent cases of RHO-associated nonsyndromic autosomal dominant retinitis pigmentosa
- Diagnosed prevalent cases of Usher syndrome
- Diagnosed prevalent cases of Usher syndrome by subtypes
- Diagnosed prevalent cases of Bardet-Biedl syndrome
- Drug-treated prevalent cases of retinitis pigmentosa
- Diagnosed prevalent cases of Leber congenital amaurosis
- Drug-treatable prevalent cases of RPE65-associated Leber congenital amaurosis
- Diagnosed prevalent cases of choroideremia
- Drug-treatable prevalent cases of choroideremia
- Risk/protective factors applied to disease forecast models
- Reference Materials
